DnB Asset Management
NKTR icon

DnB Asset Management’s Nektar Therapeutics NKTR Stock Holding History

DnB Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,980
Closed -$965K – 625
2019
Q4 		$965K Buy
2,980
+1,745
+141% +$506K 0.01% 583
2019
Q3 		$337K Buy
1,235
+32
+3% +$11.7K ﹤0.01% 622
2019
Q2 		$642K Buy
1,203
+41
+4% +$20.6K 0.01% 583
2019
Q1 		$585K Sell
1,162
-175
-13% -$104K 0.01% 587
2018
Q4 		$659K Sell
1,337
-4
-0.3% -$2.42K 0.01% 570
2018
Q3 		$1.23M Buy
1,341
+261
+24% +$223K 0.01% 507
2018
Q2 		$791K Buy
+1,080
New +$1.25M 0.01% 565

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

DnB Asset Management's NKTR Position: Q1 2020 in Review

DnB Asset Management sold out of Nektar Therapeutics (NKTR) in Q1 2020, closing a stake of 2,980 shares — an estimated $965K sold.

DnB Asset Management first reported a position in NKTR in Q2 2018 and held it in 7 quarters. The position peaked at $1.23M in Q3 2018. 244 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

  • DnB Asset Management reported no remaining Nektar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • DnB Asset Management sold 2,980 Nektar Therapeutics shares in Q1 2020, an estimated $965K.
  • DnB Asset Management first reported a position in Nektar Therapeutics in Q2 2018 and held it in 7 quarters.
  • DnB Asset Management's Nektar Therapeutics position peaked at $1.23M in Q3 2018.
  • 244 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on DnB Asset Management's 13F filing for Q1 2020, filed 17 Apr 2020.